sacituzumab
gilead
['mbc', 'tropics-02']
os analysis from tropics-02 study of sacitizumab govitecan in patients with hr+ve/her2-ve mbc. clinically meaningful benefit and independent of her2-low status. pfs and os improvement demonstrated. #asco23 
Early Career Consultant Clinical Oncologist (Breast and Thyroid Cancer). Interested in history, politics and sci-fi. Enthusiastic.Getting on with it. Views own.